In their editorial “Make lithium great again!“ Malhi and collaborators¹ reviewed the common misconceptions surrounding tolerability and ease of administration, and the clinical phenotypes to consider when prescribing lithium for bipolar disorders (BD). Despite clinical practice guidelines recommending lithium as a first‐line option in BD, its use appears to be declining. For example, in a recent analysis of prescribing practices in the USA between 1997 and 2016, lithium use in outpatients with BD declined from 30% to 18%.² Given its established efficacy, this is of serious concern. Perhaps the strongest argument promulgated by those who do not prescribe lithium is that only a third of individuals with BD have an excellent prophylactic response.

中文翻译：

---

再次使锂变得更好–精确！

在他们的社论中“再次使锂变得更好！“ Malhi及其合作者¹回顾了关于耐受性和给药简便性的常见误解，以及在为双相性精神障碍（BD）开锂处方时要考虑的临床表型。尽管临床实践指南建议将锂作为BD的首选药物，但其使用似乎正在下降。例如，在最近对1997年至2016年间美国处方实践的分析中，BD患者的门诊锂使用量从30％下降到18％。²鉴于其确定的功效，这是一个令人严重关注的问题。那些不开锂的人所发表的最有力的论据也许是，只有三分之一的BD患者具有出色的预防反应。